Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

  • Ayyildiz, Talat ;
  • Dolar, Enver ;
  • Ugras, Nesrin ;
  • Adim, Saduman Balaban ;
  • Yerci, Omer
  • Published : 2014.11.28


Introduction: Human adiponectin (ApN) is a 30 kDa glycoprotein of 244-amino acids which is extensively produced by adipocytes. ApN acts via two receptors, namely adiponectin receptor-1 (Adipo-R1) and adiponectin receptor-2 (Adipo-R2). Studies have shown the presence of Adipo-R1 and Adipo-R2 expression immunohistochemically in human colorectal cancers (CRCs). However, only a few studies exist which investigated effects of adiponectin receptor expression on CRC characteristics. Objectives: In the present study, we aimed to explore Adipo-R1/-R2 expression in human colorectal cancers and any association with clinicopathological characteristics and survival. Materials and Methods: The study enrolled 58 colorectal cancer patients with tumor resection and a control group of 30 subjects with normal colon mucosa. Results: Positivity for Adipo-R1/-R2 expression was significantly more common in the control group in comparison to the patient group (both p<0.001). There was no significant association between Adipo-R1/-R2 expression and clinicopathological characteristics including age, sex tumor location, pTNM stage, Duke's stage, metastasis, histological differentiation, perineural invasion, venous invasion sex, lymphatic invasion, cancer-related mortality, tumor size and recurrence. Adipo- R1/-R2 positivity was also not significantly linked to progression-free or overall survival [p values (0.871, 0.758) and (0.274, 0.232), respectively]. Conclusions: Although significantly reduced Adipo-R1/-R2 expression was found in colorectal cancer patients, it had no influence on survival.


Adiponectin receptor;Adipo-R1/-R2;colorectal carcinoma;prognosis


  1. Ayyildiz T, Dolar E, Ugras N, et al (2014). Lack of any prognostic relationship between adiponectin receptor (Adipo R1/R2) expression for early/advanced stage gastric cancer. Asian Pac J Cancer Prev, 15, 4711-16.
  2. Barresi V, Tuccari G, Barresi G (2009a). Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology, 41, 533-8.
  3. Barresi V, Grosso M, Giuffre G, Tuccari G, Barresi G (2009b). The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol, 62, 705-9.
  4. Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101, 2476-81
  5. Byeon JS, Jeong JY, Kim MJ, et al (2010). Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer, 127, 2758-67.
  6. Chen MW, Ye S, Zhao LL, et al (2012). Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol, 29, 3129-35.
  7. Cnop M, Havel PJ, Utzschneider KM, et al (2003). Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-69.
  8. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci, 14, 16365-85.
  9. Dal Maso L, Augustin LS, Karalis A, et al (2004). Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab, 89, 1160-3.
  10. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94.
  11. Dancey JE (2002). Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am, 16, 1101-14 .
  12. Fukumoto J, Otake T, Tajima O, et al (2008). Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci, 99, 781-6.
  13. Goldfine AB, Kahn CR (2003). Adiponectin: linking the fat cell to insulin sensitivity. Lancet, 362, 1431-2.
  14. Gonullu G, Kahraman H, Bedir A, et al (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12.
  15. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8.
  16. Ho GY, Wang T, Gunter MJ, et al (2012). Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res, 72, 3029-37.
  17. Huang S, Houghton PJ (2003). Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol, 3, 371-77.
  18. Ishikawa M, Kitayama J, Kazama S, et al (2005). Plasma adiponectin and gastric cancer. Clin Cancer Res, 11, 466-72.
  19. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.
  20. Kadowaki T, Yamauchi T, Kubota N, et al (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 116, 1784-92.
  21. Kamada Y, Matsumoto H, Tamura S, et al (2007). Hypoadiponectinemia accelerates hepatic tumor formation in nonalcoholic steatohepatitis mouse model. J Hepatol, 47, 556-64.
  22. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G (2002). Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 25, 971- 6.
  23. Kelesidis I, Kelesidis T, Mantzoros CS (2006). Adiponectin and cancer: a systematic review. Br J Cancer. 94, 1221-5.
  24. Kojima S, Kojima S, Maruyoshi H, et al (2011). Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol, 147, 371-6.
  25. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81.
  26. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of CRC. Cancer Epidemiol Biomarkers Prev, 15, 401-2.
  27. Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89,1102-7.
  28. Matsuzawa Y, Shimomura I, Kihara S, et al (2003). Importance of adipocytokines in obesity-related diseases. Horm Res, 3, 56-9.
  29. Michalakis K, Williams CJ, Mitsiades N, et al (2007). Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev, 16, 308-13.
  30. Moore LL, Bradlee ML, Singer MR, et al (2004). BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord, 28, 559-67.
  31. Murphy TK, Calle EE, Rodriguez C et al (2000). Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol, 152, 847-54.
  32. Oldham S, Hafen E (2003). Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol, 13, 79-85.
  33. Otake S, Takeda H, Suzuki Y, et al (2005). Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res, 11, 3642-6.
  34. Ouchi N, Kihara S, Arita Y, et al (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-6.
  35. Ouchi N, Kihara S, Arita Y, et al (2001). Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 103, 1057-63.
  36. Philp AJ, Campbell IG, Leet C, et al (2001). The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61, 7426-29.
  37. Rodrigues VS, Milanski M, Fagundes JJ, et al (2012). Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immuno, 170, 358-64.
  38. Saxena A, Baliga MS, Ponemone V, et al (2013). Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer. Int J Colorectal Dis, 28,1267-79
  39. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin , 62:220-41.
  40. Vogt PK (2001). PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med, 7, 482-4.
  41. Wei EK, Giovannucci E, Fuchs CS, Willet WC, Mantzoros CS (2005). Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97, 1688-94.
  42. Williams CJ, Mitsiades N, Sozopoulos E, et al (2008). Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer, 15, 289-99.
  43. Wolpin BM, Mayer RJ (2008). Systemic treatment of colorectal cancer. Gastroenterol, 134, 1296-10.
  44. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9.
  45. Yang WS, Lee WJ, Funahashi T, et al (2002). Plasma adiponectin levels in overweight and obese Asians. Obes Res, 10, 1104-10.
  46. Yoneda K, Tomimoto A, Endo H, et al (2008). Expression of adiponectin receptors, Adipo-R1 and Adipo-R2, in normal colon epithelium and colon cancer tissue. Oncol Rep, 20, 479-83.

Cited by

  1. Adipo-R1 and Adipo-R2 Expression in Colorectal Adenomas and Carcinomas vol.16, pp.1, 2015,
  2. Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study vol.16, pp.12, 2015,
  3. Adiponectin and colorectal cancer vol.47, pp.2, 2017,
  4. Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis vol.9, pp.1664-2392, 2018,
  5. Adiponectin as Link Factor between Adipose Tissue and Cancer vol.20, pp.4, 2019,